EA032294B1 - Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного - Google Patents

Info

Publication number

EA032294B1

EA032294B1 EA201400552A EA201400552A EA032294B1 EA 032294 B1 EA032294 B1 EA 032294B1 EA 201400552 A EA201400552 A EA 201400552A EA 201400552 A EA201400552 A EA 201400552A EA 032294 B1 EA032294 B1 EA 032294B1

Authority

EA

Eurasian Patent Office

Prior art keywords

additional embodiments

compound

approximately

cancer

iodophenylamino

Prior art date

2007-07-30

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 172
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 74
• 229940124530 sulfonamide Drugs 0.000 title claims description 10
• 238000011282 treatment Methods 0.000 title abstract description 63
• 150000003456 sulfonamides Chemical class 0.000 title description 6
• 239000000203 mixture Substances 0.000 claims abstract description 233
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims abstract description 99
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims abstract description 99
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 54
• 238000000113 differential scanning calorimetry Methods 0.000 claims abstract description 49
• 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 45
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims abstract description 40
• 230000001404 mediated effect Effects 0.000 claims abstract description 26
• 238000002844 melting Methods 0.000 claims abstract description 17
• 230000008018 melting Effects 0.000 claims abstract description 17
• 206010028980 Neoplasm Diseases 0.000 claims description 339
• 201000011510 cancer Diseases 0.000 claims description 218
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 164
• -1 3,4-difluoro-2- (2-fluoro-4-iodophenylamino) -6methoxyphenyl Chemical group 0.000 claims description 142
• 201000010099 disease Diseases 0.000 claims description 81
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 66
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 48
• 229940016286 microcrystalline cellulose Drugs 0.000 claims description 48
• 239000008108 microcrystalline cellulose Substances 0.000 claims description 48
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 48
• 239000002246 antineoplastic agent Substances 0.000 claims description 43
• 239000000843 powder Substances 0.000 claims description 42
• 238000002360 preparation method Methods 0.000 claims description 40
• 239000003937 drug carrier Substances 0.000 claims description 38
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 35
• 229920002785 Croscarmellose sodium Polymers 0.000 claims description 33
• 229960001681 croscarmellose sodium Drugs 0.000 claims description 33
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 33
• 235000019359 magnesium stearate Nutrition 0.000 claims description 33
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 30
• 229940127089 cytotoxic agent Drugs 0.000 claims description 30
• 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 30
• 208000027866 inflammatory disease Diseases 0.000 claims description 26
• 230000002062 proliferating effect Effects 0.000 claims description 19
• 238000001959 radiotherapy Methods 0.000 claims description 19
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 17
• 239000002254 cytotoxic agent Substances 0.000 claims description 13
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 13
• 230000001842 fibrogenetic effect Effects 0.000 claims description 9
• 102000004127 Cytokines Human genes 0.000 claims description 8
• 108090000695 Cytokines Proteins 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 238000006243 chemical reaction Methods 0.000 claims description 6
• 208000026278 immune system disease Diseases 0.000 claims description 6
• 238000004296 chiral HPLC Methods 0.000 claims description 4
• 238000002425 crystallisation Methods 0.000 claims description 4
• 230000008025 crystallization Effects 0.000 claims description 4
• 238000000926 separation method Methods 0.000 claims description 4
• 239000002002 slurry Substances 0.000 claims description 4
• 238000003756 stirring Methods 0.000 claims description 4
• 239000013543 active substance Substances 0.000 claims description 3
• 208000015181 infectious disease Diseases 0.000 claims description 3
• 239000013078 crystal Substances 0.000 claims description 2
• 239000002178 crystalline material Substances 0.000 claims description 2
• 239000011521 glass Substances 0.000 claims description 2
• 238000010438 heat treatment Methods 0.000 claims description 2
• 238000002441 X-ray diffraction Methods 0.000 claims 6
• 238000010992 reflux Methods 0.000 claims 1
• 150000001875 compounds Chemical class 0.000 abstract description 181
• RDSACQWTXKSHJT-UHFFFAOYSA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide Chemical compound C1CC1(CC(O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-UHFFFAOYSA-N 0.000 abstract 1
• 229940126062 Compound A Drugs 0.000 description 299
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 299
• 210000004027 cell Anatomy 0.000 description 161
• 239000003814 drug Substances 0.000 description 95
• 239000003112 inhibitor Substances 0.000 description 89
• 230000000694 effects Effects 0.000 description 78
• 208000035475 disorder Diseases 0.000 description 76
• 229940124597 therapeutic agent Drugs 0.000 description 65
• 241000124008 Mammalia Species 0.000 description 63
• 102000004190 Enzymes Human genes 0.000 description 55
• 108090000790 Enzymes Proteins 0.000 description 55
• 229940088598 enzyme Drugs 0.000 description 55
• 239000000546 pharmaceutical excipient Substances 0.000 description 55
• 230000035755 proliferation Effects 0.000 description 46
• 230000002401 inhibitory effect Effects 0.000 description 44
• 230000002829 reductive effect Effects 0.000 description 44
• 239000003795 chemical substances by application Substances 0.000 description 38
• 150000003839 salts Chemical class 0.000 description 38
• 230000005907 cancer growth Effects 0.000 description 32
• 230000007423 decrease Effects 0.000 description 32
• 239000000243 solution Substances 0.000 description 29
• 239000007924 injection Substances 0.000 description 26
• 238000002347 injection Methods 0.000 description 26
• 239000005557 antagonist Substances 0.000 description 25
• 229940079593 drug Drugs 0.000 description 25
• 241000282414 Homo sapiens Species 0.000 description 24
• 230000010261 cell growth Effects 0.000 description 24
• 239000003826 tablet Substances 0.000 description 24
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 23
• 239000000725 suspension Substances 0.000 description 22
• 239000002775 capsule Substances 0.000 description 21
• 239000002552 dosage form Substances 0.000 description 20
• 150000002148 esters Chemical class 0.000 description 20
• 208000032839 leukemia Diseases 0.000 description 20
• 206010039073 rheumatoid arthritis Diseases 0.000 description 20
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 19
• 230000002159 abnormal effect Effects 0.000 description 19
• 206010060862 Prostate cancer Diseases 0.000 description 18
• 230000000340 anti-metabolite Effects 0.000 description 18
• 229940100197 antimetabolite Drugs 0.000 description 18
• 239000002256 antimetabolite Substances 0.000 description 18
• 238000001802 infusion Methods 0.000 description 18
• 208000008839 Kidney Neoplasms Diseases 0.000 description 17
• 206010033128 Ovarian cancer Diseases 0.000 description 17
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 17
• 208000005718 Stomach Neoplasms Diseases 0.000 description 17
• 206010017758 gastric cancer Diseases 0.000 description 17
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 17
• 201000011549 stomach cancer Diseases 0.000 description 17
• 239000000126 substance Substances 0.000 description 17
• 208000003174 Brain Neoplasms Diseases 0.000 description 16
• 206010006187 Breast cancer Diseases 0.000 description 16
• 208000026310 Breast neoplasm Diseases 0.000 description 16
• 206010061535 Ovarian neoplasm Diseases 0.000 description 16
• 206010038389 Renal cancer Diseases 0.000 description 16
• 208000029742 colonic neoplasm Diseases 0.000 description 16
• 230000002354 daily effect Effects 0.000 description 16
• 230000003463 hyperproliferative effect Effects 0.000 description 16
• 230000005764 inhibitory process Effects 0.000 description 16
• 201000010982 kidney cancer Diseases 0.000 description 16
• 201000002528 pancreatic cancer Diseases 0.000 description 16
• 208000008443 pancreatic carcinoma Diseases 0.000 description 16
• 229940002612 prodrug Drugs 0.000 description 16
• 239000000651 prodrug Substances 0.000 description 16
• 239000012453 solvate Substances 0.000 description 16
• 238000001356 surgical procedure Methods 0.000 description 16
• 229940100198 alkylating agent Drugs 0.000 description 15
• 239000002168 alkylating agent Substances 0.000 description 15
• 230000003388 anti-hormonal effect Effects 0.000 description 15
• 230000008901 benefit Effects 0.000 description 15
• 230000037396 body weight Effects 0.000 description 15
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 15
• 239000003102 growth factor Substances 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 15
• 206010009944 Colon cancer Diseases 0.000 description 14
• 208000015634 Rectal Neoplasms Diseases 0.000 description 14
• 210000001072 colon Anatomy 0.000 description 14
• 239000000367 immunologic factor Substances 0.000 description 14
• 208000002193 Pain Diseases 0.000 description 13
• 239000000556 agonist Substances 0.000 description 13
• 239000007788 liquid Substances 0.000 description 13
• 239000003909 protein kinase inhibitor Substances 0.000 description 13
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 12
• 229930012538 Paclitaxel Natural products 0.000 description 12
• 238000011374 additional therapy Methods 0.000 description 12
• 208000009956 adenocarcinoma Diseases 0.000 description 12
• 238000011360 adjunctive therapy Methods 0.000 description 12
• 229940043355 kinase inhibitor Drugs 0.000 description 12
• 201000005202 lung cancer Diseases 0.000 description 12
• 208000020816 lung neoplasm Diseases 0.000 description 12
• 230000003211 malignant effect Effects 0.000 description 12
• 229960001592 paclitaxel Drugs 0.000 description 12
• 230000036407 pain Effects 0.000 description 12
• 229910052697 platinum Inorganic materials 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 201000004681 Psoriasis Diseases 0.000 description 11
• 150000001408 amides Chemical class 0.000 description 11
• 230000000259 anti-tumor effect Effects 0.000 description 11
• 238000002512 chemotherapy Methods 0.000 description 11
• 239000003085 diluting agent Substances 0.000 description 11
• 239000000839 emulsion Substances 0.000 description 11
• 239000003966 growth inhibitor Substances 0.000 description 11
• 230000003394 haemopoietic effect Effects 0.000 description 11
• 230000003054 hormonal effect Effects 0.000 description 11
• 238000001990 intravenous administration Methods 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• 125000002456 taxol group Chemical group 0.000 description 11
• 201000001320 Atherosclerosis Diseases 0.000 description 10
• 208000023275 Autoimmune disease Diseases 0.000 description 10
• 241000282412 Homo Species 0.000 description 10
• 206010039710 Scleroderma Diseases 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 10
• 239000006071 cream Substances 0.000 description 10
• JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 10
• 229960003572 cyclobenzaprine Drugs 0.000 description 10
• 210000003491 skin Anatomy 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• 201000009030 Carcinoma Diseases 0.000 description 9
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 9
• 229920002472 Starch Polymers 0.000 description 9
• 230000006907 apoptotic process Effects 0.000 description 9
• 239000011230 binding agent Substances 0.000 description 9
• 239000000969 carrier Substances 0.000 description 9
• 238000007918 intramuscular administration Methods 0.000 description 9
• 229960004194 lidocaine Drugs 0.000 description 9
• 201000001441 melanoma Diseases 0.000 description 9
• 230000005855 radiation Effects 0.000 description 9
• 210000000664 rectum Anatomy 0.000 description 9
• 239000008107 starch Substances 0.000 description 9
• 229940032147 starch Drugs 0.000 description 9
• 235000019698 starch Nutrition 0.000 description 9
• 238000007920 subcutaneous administration Methods 0.000 description 9
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 210000003719 b-lymphocyte Anatomy 0.000 description 8
• 239000000796 flavoring agent Substances 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 208000028867 ischemia Diseases 0.000 description 8
• 239000000314 lubricant Substances 0.000 description 8
• 239000002674 ointment Substances 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 206010038038 rectal cancer Diseases 0.000 description 8
• 201000001275 rectum cancer Diseases 0.000 description 8
• 208000037803 restenosis Diseases 0.000 description 8
• 239000000375 suspending agent Substances 0.000 description 8
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 7
• 108010010803 Gelatin Proteins 0.000 description 7
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 7
• 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 7
• 108060006687 MAP kinase kinase kinase Proteins 0.000 description 7
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
• 239000003086 colorant Substances 0.000 description 7
• 239000002270 dispersing agent Substances 0.000 description 7
• 239000000945 filler Substances 0.000 description 7
• 239000008273 gelatin Substances 0.000 description 7
• 229920000159 gelatin Polymers 0.000 description 7
• 235000019322 gelatine Nutrition 0.000 description 7
• 235000011852 gelatine desserts Nutrition 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 208000005987 polymyositis Diseases 0.000 description 7
• 239000003755 preservative agent Substances 0.000 description 7
• 206010041823 squamous cell carcinoma Diseases 0.000 description 7
• 239000000829 suppository Substances 0.000 description 7
• 239000004094 surface-active agent Substances 0.000 description 7
• 239000003765 sweetening agent Substances 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 239000000080 wetting agent Substances 0.000 description 7
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
• 206010016654 Fibrosis Diseases 0.000 description 6
• 201000005569 Gout Diseases 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 208000029523 Interstitial Lung disease Diseases 0.000 description 6
• 229940124647 MEK inhibitor Drugs 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
• 230000009471 action Effects 0.000 description 6
• 206010003246 arthritis Diseases 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 6
• 230000007882 cirrhosis Effects 0.000 description 6
• 208000019425 cirrhosis of liver Diseases 0.000 description 6
• 235000014113 dietary fatty acids Nutrition 0.000 description 6
• 210000001508 eye Anatomy 0.000 description 6
• 239000000194 fatty acid Substances 0.000 description 6
• 229930195729 fatty acid Natural products 0.000 description 6
• 235000003599 food sweetener Nutrition 0.000 description 6
• 239000003018 immunosuppressive agent Substances 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 201000006334 interstitial nephritis Diseases 0.000 description 6
• 208000011379 keloid formation Diseases 0.000 description 6
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 6
• 229960000991 ketoprofen Drugs 0.000 description 6
• 239000008101 lactose Substances 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 206010025135 lupus erythematosus Diseases 0.000 description 6
• 230000036210 malignancy Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 210000000214 mouth Anatomy 0.000 description 6
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 210000001672 ovary Anatomy 0.000 description 6
• 208000000587 small cell lung carcinoma Diseases 0.000 description 6
• 230000009885 systemic effect Effects 0.000 description 6
• 239000000454 talc Substances 0.000 description 6
• 229910052623 talc Inorganic materials 0.000 description 6
• 229940033134 talc Drugs 0.000 description 6
• 235000012222 talc Nutrition 0.000 description 6
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
• 244000215068 Acacia senegal Species 0.000 description 5
• 206010000830 Acute leukaemia Diseases 0.000 description 5
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
• 206010004146 Basal cell carcinoma Diseases 0.000 description 5
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
• 206010013774 Dry eye Diseases 0.000 description 5
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
• 229920000084 Gum arabic Polymers 0.000 description 5
• 206010020751 Hypersensitivity Diseases 0.000 description 5
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• 206010033645 Pancreatitis Diseases 0.000 description 5
• 206010041067 Small cell lung cancer Diseases 0.000 description 5
• 235000010489 acacia gum Nutrition 0.000 description 5
• 239000000205 acacia gum Substances 0.000 description 5
• 230000007815 allergy Effects 0.000 description 5
• 230000033115 angiogenesis Effects 0.000 description 5
• 230000002280 anti-androgenic effect Effects 0.000 description 5
• 239000000051 antiandrogen Substances 0.000 description 5
• 239000002220 antihypertensive agent Substances 0.000 description 5
• 239000003963 antioxidant agent Substances 0.000 description 5
• 235000006708 antioxidants Nutrition 0.000 description 5
• 239000007900 aqueous suspension Substances 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 239000003405 delayed action preparation Substances 0.000 description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
• 229960003957 dexamethasone Drugs 0.000 description 5
• 150000004665 fatty acids Chemical class 0.000 description 5
• 208000005017 glioblastoma Diseases 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• 239000008187 granular material Substances 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 239000007937 lozenge Substances 0.000 description 5
• 208000030159 metabolic disease Diseases 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• 201000008482 osteoarthritis Diseases 0.000 description 5
• 239000000825 pharmaceutical preparation Substances 0.000 description 5
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 210000002307 prostate Anatomy 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 239000008174 sterile solution Substances 0.000 description 5
• 238000012384 transportation and delivery Methods 0.000 description 5
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 4
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 4
• 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 4
• 206010003571 Astrocytoma Diseases 0.000 description 4
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 4
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 4
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
• 206010009900 Colitis ulcerative Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
• 108010036949 Cyclosporine Proteins 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 206010018338 Glioma Diseases 0.000 description 4
• HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 4
• 208000007766 Kaposi sarcoma Diseases 0.000 description 4
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 4
• 206010027406 Mesothelioma Diseases 0.000 description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
• 208000005890 Neuroma Diseases 0.000 description 4
• 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
• 108090000184 Selectins Proteins 0.000 description 4
• 102000003800 Selectins Human genes 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 4
• 229940030600 antihypertensive agent Drugs 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• 229960002170 azathioprine Drugs 0.000 description 4
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
• 229960000794 baclofen Drugs 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 229960000623 carbamazepine Drugs 0.000 description 4
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 229960001265 ciclosporin Drugs 0.000 description 4
• 229960002896 clonidine Drugs 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• 229930182912 cyclosporin Natural products 0.000 description 4
• 229960002593 desoximetasone Drugs 0.000 description 4
• VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000007580 dry-mixing Methods 0.000 description 4
• 230000002526 effect on cardiovascular system Effects 0.000 description 4
• 239000010685 fatty oil Substances 0.000 description 4
• 201000003444 follicular lymphoma Diseases 0.000 description 4
• 229960002870 gabapentin Drugs 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 229960002146 guaifenesin Drugs 0.000 description 4
• 230000002489 hematologic effect Effects 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 239000007943 implant Substances 0.000 description 4
• 239000012444 intercalating antibiotic Substances 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 229940057995 liquid paraffin Drugs 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 229960004584 methylprednisolone Drugs 0.000 description 4
• 239000004530 micro-emulsion Substances 0.000 description 4
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
• 230000011278 mitosis Effects 0.000 description 4
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
• 208000025113 myeloid leukemia Diseases 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 239000006072 paste Substances 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 229960004618 prednisone Drugs 0.000 description 4
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000000770 proinflammatory effect Effects 0.000 description 4
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 4
• 150000003180 prostaglandins Chemical class 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 239000002464 receptor antagonist Substances 0.000 description 4
• 229940044551 receptor antagonist Drugs 0.000 description 4
• 238000006722 reduction reaction Methods 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 229960004793 sucrose Drugs 0.000 description 4
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
• 201000002510 thyroid cancer Diseases 0.000 description 4
• 238000011200 topical administration Methods 0.000 description 4
• 210000003932 urinary bladder Anatomy 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• 238000005550 wet granulation Methods 0.000 description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
• 206010053555 Arthritis bacterial Diseases 0.000 description 3
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 206010006811 Bursitis Diseases 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 241000792859 Enema Species 0.000 description 3
• 241000402754 Erythranthe moschata Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 208000007882 Gastritis Diseases 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 206010018634 Gouty Arthritis Diseases 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
• 208000014767 Myeloproliferative disease Diseases 0.000 description 3
• BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
• 208000017442 Retinal disease Diseases 0.000 description 3
• 201000000582 Retinoblastoma Diseases 0.000 description 3
• 206010038923 Retinopathy Diseases 0.000 description 3
• 229930189077 Rifamycin Natural products 0.000 description 3
• 208000008765 Sciatica Diseases 0.000 description 3
• 208000000453 Skin Neoplasms Diseases 0.000 description 3
• 208000006045 Spondylarthropathies Diseases 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 208000000491 Tendinopathy Diseases 0.000 description 3
• 206010043255 Tendonitis Diseases 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 239000000783 alginic acid Substances 0.000 description 3
• 229960001126 alginic acid Drugs 0.000 description 3
• 150000004781 alginic acids Chemical class 0.000 description 3
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
• 230000003078 antioxidant effect Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 208000010668 atopic eczema Diseases 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 229910000019 calcium carbonate Inorganic materials 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 229960002504 capsaicin Drugs 0.000 description 3
• 235000017663 capsaicin Nutrition 0.000 description 3
• 208000002458 carcinoid tumor Diseases 0.000 description 3
• 210000003679 cervix uteri Anatomy 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 239000007859 condensation product Substances 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 229960000913 crospovidone Drugs 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 229940088679 drug related substance Drugs 0.000 description 3
• 239000007920 enema Substances 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 235000019634 flavors Nutrition 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 150000002303 glucose derivatives Chemical class 0.000 description 3
• 230000009036 growth inhibition Effects 0.000 description 3
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 206010020718 hyperplasia Diseases 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 229960000598 infliximab Drugs 0.000 description 3
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 230000037353 metabolic pathway Effects 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 229940124303 multikinase inhibitor Drugs 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 208000004296 neuralgia Diseases 0.000 description 3
• 230000002981 neuropathic effect Effects 0.000 description 3
• 208000021722 neuropathic pain Diseases 0.000 description 3
• 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 229960002450 ofatumumab Drugs 0.000 description 3
• 239000004006 olive oil Substances 0.000 description 3
• 235000008390 olive oil Nutrition 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 210000003800 pharynx Anatomy 0.000 description 3
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229960001807 prilocaine Drugs 0.000 description 3
• MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 208000005069 pulmonary fibrosis Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 210000002345 respiratory system Anatomy 0.000 description 3
• 229960003292 rifamycin Drugs 0.000 description 3
• HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 3
• CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 3
• 201000000849 skin cancer Diseases 0.000 description 3
• 229920003109 sodium starch glycolate Polymers 0.000 description 3
• 229940079832 sodium starch glycolate Drugs 0.000 description 3
• 239000008109 sodium starch glycolate Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 201000005671 spondyloarthropathy Diseases 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 201000004415 tendinitis Diseases 0.000 description 3
• 229960003604 testosterone Drugs 0.000 description 3
• 239000002562 thickening agent Substances 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 206010044412 transitional cell carcinoma Diseases 0.000 description 3
• 238000011269 treatment regimen Methods 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• 201000005112 urinary bladder cancer Diseases 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 2
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 102100032534 Adenosine kinase Human genes 0.000 description 2
• 108020000543 Adenylate kinase Proteins 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 101710145634 Antigen 1 Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 208000019838 Blood disease Diseases 0.000 description 2
• 206010006542 Bulbar palsy Diseases 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 101100386518 Caenorhabditis elegans dbl-1 gene Proteins 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
• 102000005600 Cathepsins Human genes 0.000 description 2
• 108010084457 Cathepsins Proteins 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 229940105129 Chemotaxis inhibitor Drugs 0.000 description 2
• 208000000094 Chronic Pain Diseases 0.000 description 2
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
• 241000723346 Cinnamomum camphora Species 0.000 description 2
• GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
• 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
• 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 2
• 108010024212 E-Selectin Proteins 0.000 description 2
• 102100023471 E-selectin Human genes 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• 239000001293 FEMA 3089 Substances 0.000 description 2
• UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 2
• WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 206010022489 Insulin Resistance Diseases 0.000 description 2
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
• 101150100676 Map2k1 gene Proteins 0.000 description 2
• 208000000172 Medulloblastoma Diseases 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 102000008108 Osteoprotegerin Human genes 0.000 description 2
• 108010035042 Osteoprotegerin Proteins 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 102100023472 P-selectin Human genes 0.000 description 2
• 101150062589 PTGS1 gene Proteins 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 206010033647 Pancreatitis acute Diseases 0.000 description 2
• 206010033649 Pancreatitis chronic Diseases 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• 108010068701 Pegloticase Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 206010038687 Respiratory distress Diseases 0.000 description 2
• 208000025747 Rheumatic disease Diseases 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• 201000010208 Seminoma Diseases 0.000 description 2
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 201000005969 Uveal melanoma Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 201000003229 acute pancreatitis Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
• 229960003459 allopurinol Drugs 0.000 description 2
• 239000002160 alpha blocker Substances 0.000 description 2
• 229960003099 amcinonide Drugs 0.000 description 2
• ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960000836 amitriptyline Drugs 0.000 description 2
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
• 229960002519 amoxapine Drugs 0.000 description 2
• QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940046836 anti-estrogen Drugs 0.000 description 2
• 230000001833 anti-estrogenic effect Effects 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 239000003435 antirheumatic agent Substances 0.000 description 2
• 239000000305 astragalus gummifer gum Substances 0.000 description 2
• AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
• 229960005207 auranofin Drugs 0.000 description 2
• 201000004983 autoimmune atherosclerosis Diseases 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
• 229960002529 benzbromarone Drugs 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 229960001102 betamethasone dipropionate Drugs 0.000 description 2
• CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
• 229960004311 betamethasone valerate Drugs 0.000 description 2
• SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 2
• 229960002470 bimatoprost Drugs 0.000 description 2
• AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 229960000846 camphor Drugs 0.000 description 2
• 229930008380 camphor Natural products 0.000 description 2
• 229930003827 cannabinoid Natural products 0.000 description 2
• 239000003557 cannabinoid Substances 0.000 description 2
• 229940065144 cannabinoids Drugs 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 229960000590 celecoxib Drugs 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 239000002819 chemotaxis inhibitor Substances 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• 229960004703 clobetasol propionate Drugs 0.000 description 2
• CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
• 229960004606 clomipramine Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 229960004126 codeine Drugs 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 229960001338 colchicine Drugs 0.000 description 2
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
• 201000010989 colorectal carcinoma Diseases 0.000 description 2
• LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 2
• 108010073240 complement C5a-inhibitors Proteins 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 238000002316 cosmetic surgery Methods 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 229960001251 denosumab Drugs 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229960003914 desipramine Drugs 0.000 description 2
• 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
• 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 2
• 229960001259 diclofenac Drugs 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• 229960002124 diflorasone diacetate Drugs 0.000 description 2
• BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 229960005426 doxepin Drugs 0.000 description 2
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 229960002866 duloxetine Drugs 0.000 description 2
• 239000003602 elastase inhibitor Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 229940095399 enema Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 229960001842 estramustine Drugs 0.000 description 2
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
• 239000000328 estrogen antagonist Substances 0.000 description 2
• JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 2
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
• 229960005293 etodolac Drugs 0.000 description 2
• 239000010642 eucalyptus oil Substances 0.000 description 2
• 229940044949 eucalyptus oil Drugs 0.000 description 2
• 239000000374 eutectic mixture Substances 0.000 description 2
• 239000003172 expectorant agent Substances 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 210000001752 female genitalia Anatomy 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 229940043075 fluocinolone Drugs 0.000 description 2
• 229960000785 fluocinonide Drugs 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• 239000012213 gelatinous substance Substances 0.000 description 2
• 210000004392 genitalia Anatomy 0.000 description 2
• 150000002344 gold compounds Chemical class 0.000 description 2
• 238000000227 grinding Methods 0.000 description 2
• 201000010536 head and neck cancer Diseases 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000014951 hematologic disease Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
• 229960004171 hydroxychloroquine Drugs 0.000 description 2
• 229960003943 hypromellose Drugs 0.000 description 2
• 229960002491 ibudilast Drugs 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 229960000908 idarubicin Drugs 0.000 description 2
• 229960004801 imipramine Drugs 0.000 description 2
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 229940124589 immunosuppressive drug Drugs 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229960001888 ipratropium Drugs 0.000 description 2
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 208000003849 large cell carcinoma Diseases 0.000 description 2
• 206010023841 laryngeal neoplasm Diseases 0.000 description 2
• GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
• 229960001160 latanoprost Drugs 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 229960000681 leflunomide Drugs 0.000 description 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 230000011268 leukocyte chemotaxis Effects 0.000 description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
• 229960004338 leuprorelin Drugs 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 239000003589 local anesthetic agent Substances 0.000 description 2
• 229960005015 local anesthetics Drugs 0.000 description 2
• RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
• 229960001571 loperamide Drugs 0.000 description 2
• 208000012804 lymphangiosarcoma Diseases 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 229960003404 mexiletine Drugs 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 2
• 229960004023 minocycline Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 229960005127 montelukast Drugs 0.000 description 2
• 229960005181 morphine Drugs 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
• 229960004398 nedocromil Drugs 0.000 description 2
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229960001158 nortriptyline Drugs 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 230000000771 oncological effect Effects 0.000 description 2
• 229940005483 opioid analgesics Drugs 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 210000003300 oropharynx Anatomy 0.000 description 2
• 229960001816 oxcarbazepine Drugs 0.000 description 2
• CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
• HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 2
• 210000000277 pancreatic duct Anatomy 0.000 description 2
• 229960005489 paracetamol Drugs 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 208000000689 peptic esophagitis Diseases 0.000 description 2
• 239000003358 phospholipase A2 inhibitor Substances 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• 229960002702 piroxicam Drugs 0.000 description 2
• 229950010765 pivalate Drugs 0.000 description 2
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 229940069328 povidone Drugs 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 201000002241 progressive bulbar palsy Diseases 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 229960002601 protriptyline Drugs 0.000 description 2
• BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 2
• 230000006824 pyrimidine synthesis Effects 0.000 description 2
• 108091006084 receptor activators Proteins 0.000 description 2
• 210000004994 reproductive system Anatomy 0.000 description 2
• 150000003873 salicylate salts Chemical class 0.000 description 2
• 229960004017 salmeterol Drugs 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 238000011125 single therapy Methods 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 229940005550 sodium alginate Drugs 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• QHJLLDJTVQAFAN-UHFFFAOYSA-M sodium meclofenamate monohydrate Chemical compound O.[Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl QHJLLDJTVQAFAN-UHFFFAOYSA-M 0.000 description 2
• 239000007901 soft capsule Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229960000278 theophylline Drugs 0.000 description 2
• 238000002411 thermogravimetry Methods 0.000 description 2
• 238000001757 thermogravimetry curve Methods 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 229960004380 tramadol Drugs 0.000 description 2
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
• 229960002368 travoprost Drugs 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 229950008396 ulobetasol propionate Drugs 0.000 description 2
• BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
• 229960002911 zonisamide Drugs 0.000 description 2
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
• HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
• BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• KOKTUHPFPWFELE-HCWSKCQFSA-N 1-[(2s,3r,4s,5r)-2-fluoro-3,4-dihydroxy-5-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@@]1(F)N1C(=O)NC(=O)C=C1 KOKTUHPFPWFELE-HCWSKCQFSA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
• QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
• YTVCXBVFGQEBAL-ARJAWSKDSA-N 2-methoxy-5-[(z)-2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]phenol Chemical compound C=1C=2OCOC=2C(OC)=CC=1\C=C/C1=CC=C(OC)C(O)=C1 YTVCXBVFGQEBAL-ARJAWSKDSA-N 0.000 description 1
• FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
• PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
• XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 206010003253 Arthritis enteropathic Diseases 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
• 102000016605 B-Cell Activating Factor Human genes 0.000 description 1
• 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 206010061728 Bone lesion Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 101100291853 Caenorhabditis briggsae uba-4 gene Proteins 0.000 description 1
• 101100291854 Caenorhabditis elegans moc-3 gene Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 102100027995 Collagenase 3 Human genes 0.000 description 1
• 108050005238 Collagenase 3 Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102000034534 Cotransporters Human genes 0.000 description 1
• 108020003264 Cotransporters Proteins 0.000 description 1
• 241000065675 Cyclops Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 102000003849 Cytochrome P450 Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
• 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
• 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108010011459 Exenatide Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 206010061968 Gastric neoplasm Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
• 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
• 108010001483 Glycogen Synthase Proteins 0.000 description 1
• 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 102100022087 Granzyme M Human genes 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 102100024025 Heparanase Human genes 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 241000282418 Hominidae Species 0.000 description 1
• 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
• 101000900697 Homo sapiens Granzyme M Proteins 0.000 description 1
• 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 102100035792 Kininogen-1 Human genes 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 208000034800 Leukoencephalopathies Diseases 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
• LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
• 229940095083 Lymphocyte stimulant Drugs 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
• 229940124761 MMP inhibitor Drugs 0.000 description 1
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
• 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
• 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
• 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100030417 Matrilysin Human genes 0.000 description 1
• 108090000855 Matrilysin Proteins 0.000 description 1
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
• 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 206010027193 Meningioma malignant Diseases 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101710161855 Methionine aminopeptidase 1 Proteins 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 206010027603 Migraine headaches Diseases 0.000 description 1
• UZUUQCBCWDBYCG-UHFFFAOYSA-N Mitomycin B Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(O)N2CC2C1N2C UZUUQCBCWDBYCG-UHFFFAOYSA-N 0.000 description 1
• HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 101710103983 Modulator of apoptosis 1 Proteins 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 101710204212 Neocarzinostatin Proteins 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 101100309040 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) lea-1 gene Proteins 0.000 description 1
• 102100030411 Neutrophil collagenase Human genes 0.000 description 1
• 101710118230 Neutrophil collagenase Proteins 0.000 description 1
• 102000010410 Nogo Proteins Human genes 0.000 description 1
• 108010077641 Nogo Proteins Proteins 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 206010030216 Oesophagitis Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 206010033963 Parathyroid tumour Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010061336 Pelvic neoplasm Diseases 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 206010034960 Photophobia Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 208000021738 Plummer disease Diseases 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• HRHKSTOGXBBQCB-UHFFFAOYSA-N Porfiromycine Chemical compound O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 101100057145 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cta4 gene Proteins 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 102100030416 Stromelysin-1 Human genes 0.000 description 1
• 101710108790 Stromelysin-1 Proteins 0.000 description 1
• 102100028848 Stromelysin-2 Human genes 0.000 description 1
• 101710108792 Stromelysin-2 Proteins 0.000 description 1
• 102100028847 Stromelysin-3 Human genes 0.000 description 1
• 108050005271 Stromelysin-3 Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 102000018692 Sulfonylurea Receptors Human genes 0.000 description 1
• 108010091821 Sulfonylurea Receptors Proteins 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 108091033399 Telomestatin Proteins 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000000728 Thymus Neoplasms Diseases 0.000 description 1
• 206010043781 Thyroiditis chronic Diseases 0.000 description 1
• 206010062129 Tongue neoplasm Diseases 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
• LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
• IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
• XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
• 229960002632 acarbose Drugs 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229960001456 adenosine triphosphate Drugs 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000001166 anti-perspirative effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000003356 anti-rheumatic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
• 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
• 239000003213 antiperspirant Substances 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 201000005000 autoimmune gastritis Diseases 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 239000000022 bacteriostatic agent Substances 0.000 description 1
• 208000003373 basosquamous carcinoma Diseases 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 229960003679 brimonidine Drugs 0.000 description 1
• HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
• 229960000722 brinzolamide Drugs 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
• 229960001113 butorphanol Drugs 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 238000007707 calorimetry Methods 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 208000025188 carcinoma of pharynx Diseases 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• 229930188550 carminomycin Natural products 0.000 description 1
• XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 210000000860 cochlear nerve Anatomy 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• HRRAOGKGGZFKSW-UHFFFAOYSA-N combretastatin A2 Natural products COc1ccc(C=C/c2cc(O)c3OCOc3c2)cc1OC HRRAOGKGGZFKSW-UHFFFAOYSA-N 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000011961 computed axial tomography Methods 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 238000010411 cooking Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 229950003913 detorubicin Drugs 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
• 229960003933 dorzolamide Drugs 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000003248 enzyme activator Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 208000006881 esophagitis Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 229960001519 exenatide Drugs 0.000 description 1
• 230000003419 expectorant effect Effects 0.000 description 1
• 229940066493 expectorants Drugs 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 229960002848 formoterol Drugs 0.000 description 1
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 229960001442 gonadorelin Drugs 0.000 description 1
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
• 208000030316 grade III meningioma Diseases 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 201000010235 heart cancer Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 108010037536 heparanase Proteins 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 230000002473 insulinotropic effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
• 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229940095437 iopidine Drugs 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• 239000002973 irritant agent Substances 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 229960004771 levobetaxolol Drugs 0.000 description 1
• 229960000831 levobunolol Drugs 0.000 description 1
• IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
• 229960003406 levorphanol Drugs 0.000 description 1
• 210000002332 leydig cell Anatomy 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 229940040145 liniment Drugs 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 229940125389 long-acting beta agonist Drugs 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000000260 male genitalia Anatomy 0.000 description 1
• 201000010904 malignant hemangioma Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
• 229960002900 methylcellulose Drugs 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
• 239000003604 miotic agent Substances 0.000 description 1
• HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 description 1
• UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 201000010225 mixed cell type cancer Diseases 0.000 description 1
• 208000029638 mixed neoplasm Diseases 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 229940035363 muscle relaxants Drugs 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 239000003158 myorelaxant agent Substances 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 208000013315 neuromuscular junction disease Diseases 0.000 description 1
• 150000002828 nitro derivatives Chemical class 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 229940060184 oil ingredients Drugs 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
• 229950008017 ormaplatin Drugs 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 208000011937 ovarian epithelial tumor Diseases 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 235000021400 peanut butter Nutrition 0.000 description 1
• 229960001744 pegaspargase Drugs 0.000 description 1
• 108010001564 pegaspargase Proteins 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 229950003203 pexelizumab Drugs 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 150000003058 platinum compounds Chemical class 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 208000030266 primary brain neoplasm Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 239000012925 reference material Substances 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229950009213 rubitecan Drugs 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
• 229960004937 saxagliptin Drugs 0.000 description 1
• 108010033693 saxagliptin Proteins 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
• 229960004034 sitagliptin Drugs 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229940083542 sodium Drugs 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 229950006451 sorbitan laurate Drugs 0.000 description 1
• 229940035044 sorbitan monolaurate Drugs 0.000 description 1
• 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 229950004959 sorbitan oleate Drugs 0.000 description 1
• 229950003429 sorbitan palmitate Drugs 0.000 description 1
• 229950011392 sorbitan stearate Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000002336 sorption--desorption measurement Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 238000005563 spheronization Methods 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 239000006068 taste-masking agent Substances 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 239000003277 telomerase inhibitor Substances 0.000 description 1
• YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000009377 thymus cancer Diseases 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 229940028300 tigan Drugs 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 229950000212 trioxifene Drugs 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
• 229960004317 unoprostone Drugs 0.000 description 1
• TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 201000004435 urinary system cancer Diseases 0.000 description 1
• 208000023747 urothelial carcinoma Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• 239000002966 varnish Substances 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
• 229960001254 vildagliptin Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 229960004764 zafirlukast Drugs 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1